英国MHRA-话题@MedSci

#英国MHRA#

8篇内容 | 705人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1648491, encodeId=316d1648491d1, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌, objectType=article, longId=301596, objectId=a1cb301596e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1cb301596e2, replyNumber=0, likeNumber=41, createdTime=2022-11-15, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1cb301596e2, moduleTitle=武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1cb301596e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648492, encodeId=f77716484926a, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=阿斯利康的抗体鸡尾酒Evusheld获得英国MHRA授权，用以COVID-19暴露前预防, objectType=article, longId=301600, objectId=c3fb301600fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fb301600fe, replyNumber=0, likeNumber=32, createdTime=2022-09-12, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fb301600fe, moduleTitle=阿斯利康的抗体鸡尾酒Evusheld获得英国MHRA授权，用以COVID-19暴露前预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fb301600fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648493, encodeId=55861648493d3, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见, objectType=article, longId=723941, objectId=864ae239414f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864ae239414f, replyNumber=0, likeNumber=34, createdTime=2022-07-08, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864ae239414f, moduleTitle=英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864ae239414f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648489, encodeId=3c9616484891e, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=英国MHRA开始对Moderna新冠病毒疫苗进行滚动审查, objectType=article, longId=202781, objectId=1ae1202e815f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ae1202e815f, replyNumber=0, likeNumber=38, createdTime=2021-06-13, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ae1202e815f, moduleTitle=英国MHRA开始对Moderna新冠病毒疫苗进行滚动审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ae1202e815f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648490, encodeId=d52a1648490f4, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=英国MHRA允许开展阿霉素“前药”AVA6000治疗实体瘤的临床试验, objectType=article, longId=207393, objectId=6e4620e39317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e4620e39317, replyNumber=0, likeNumber=36, createdTime=2021-12-02, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e4620e39317, moduleTitle=英国MHRA允许开展阿霉素“前药”AVA6000治疗实体瘤的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e4620e39317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648488, encodeId=4d9316484884b, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=RNAi疗法lumasiran：获得英国MHRA支持治疗1型原发性高草酸尿症, objectType=article, longId=197645, objectId=e51219e64512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e51219e64512, replyNumber=0, likeNumber=30, createdTime=2021-03-19, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e51219e64512, moduleTitle=RNAi疗法lumasiran：获得英国MHRA支持治疗1型原发性高草酸尿症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e51219e64512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648487, encodeId=054a164848e38, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=英国MHRA为Vamorolone授予创新药物称号（PIM），用于治疗Duchenne肌营养不良, objectType=article, longId=181707, objectId=6c06181e0759, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c06181e0759, replyNumber=0, likeNumber=30, createdTime=2020-07-07, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c06181e0759, moduleTitle=英国MHRA为Vamorolone授予创新药物称号（PIM），用于治疗Duchenne肌营养不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c06181e0759)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648486, encodeId=6faa1648486fa, content=<a href='/topic/show?id=c3b68e084ff' target=_blank style='color:#2F92EE;'>#英国MHRA#</a>, objectTitle=英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定, objectType=article, longId=176035, objectId=15c61e603593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c61e603593, replyNumber=0, likeNumber=33, createdTime=2020-05-04, rootId=0, userName=minzju5060, userId=e32f23584568, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c61e603593, moduleTitle=英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c61e603593)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

英国MHRA

2020-05-29

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌

2022-11-15

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

阿斯利康的抗体鸡尾酒Evusheld获得英国MHRA授权，用以COVID-19暴露前预防

2022-09-12

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见

2022-07-08

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

英国MHRA开始对Moderna新冠病毒疫苗进行滚动审查

2021-06-13

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

英国MHRA允许开展阿霉素“前药”AVA6000治疗实体瘤的临床试验

2021-12-02

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

RNAi疗法lumasiran：获得英国MHRA支持治疗1型原发性高草酸尿症

2021-03-19

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

英国MHRA为Vamorolone授予创新药物称号（PIM），用于治疗Duchenne肌营养不良

2020-07-07

minzju5060 (审核中...)

前往app查看评论内容

#英国MHRA#

英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定

2020-05-04

科室
- - 订阅+
  - 更多科室
工具
服务